<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079919</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 678354-CS5</org_study_id>
    <secondary_id>2021-002192-19</secondary_id>
    <nct_id>NCT05079919</nct_id>
  </id_info>
  <brief_title>A Study of ISIS 678354 Administered to Participants With Severe Hypertriglyceridemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of ISIS 678354 as compared to placebo on&#xD;
      the percent change in fasting triglycerides (TG) from baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study in up to&#xD;
      approximately 450 participants. Participants will be randomized to receive ISIS 678354 or&#xD;
      placebo in a 53-week treatment period. The length of participation in the study will be&#xD;
      approximately 74 weeks, which includes an up to 8-week screening period, a 53-week treatment&#xD;
      period, and a 13-week post-treatment evaluation period or transition to open-label extension&#xD;
      (OLE) study with up to 1-year treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Fasting TG at 6 Months (Average of Weeks 23, 25, and 27) Compared to Placebo</measure>
    <time_frame>Baseline and Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting TG at 12 Months (Average of Weeks 51 and 53) Compared to Placebo</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Fasting TG Less Than (&lt;) 500 milligrams per deciliter (mg/dL) (5.7 millimoles per liter [mmol/L]) at 6 and 12 Months Compared to Placebo</measure>
    <time_frame>Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Fasting TG &lt; 880 mg/dL (10 mmol/L) at 6 and 12 Months Compared to Placebo in the Subgroup of Participants with Baseline TG ≥ 880 mg/dL</measure>
    <time_frame>Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Fasting TG &lt; 1000 mg/dL (11.29 mmol/L) at 6 and 12 Months Compared to Placebo in the Subgroup of Participants with Baseline TG ≥ 1000 mg/dL</measure>
    <time_frame>Month 6 and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III) at 6 and 12 Months Compared to Placebo</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Very Low-Density Lipoprotein Cholesterol (VLDL-C) at 6 and 12 Months Compared to Placebo</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at 6 and 12 Months Compared to Placebo</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at 6 and 12 Months Compared to Placebo</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo, in Participants with ≥ 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Enrollment</measure>
    <time_frame>Week 1 through Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo</measure>
    <time_frame>Week 1 through Week 53</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Severe Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>ISIS 678354</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISIS 678354 will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ISIS 678354-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 678354</intervention_name>
    <description>ISIS 678354 will be administered by SC injection.</description>
    <arm_group_label>ISIS 678354</arm_group_label>
    <other_name>AKCEA-APOCIII-LRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ISIS 678354-matching placebo will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification&#xD;
&#xD;
          -  Patients should be on standard of care lipid-lowering medications per local guidelines&#xD;
             unless intolerant. Lipid-lowering medications should be optimized and stabilized for&#xD;
             at least 4 weeks prior to Screening to minimize changes in these medications during&#xD;
             the study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening&#xD;
&#xD;
          -  Platelet count &lt; 100K/cubic millimeters at Screening or Qualification&#xD;
&#xD;
          -  Alanine aminotransferase or aspartate aminotransferase &gt; 3.0 × upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &gt; upper limit of normal unless due to Gilbert's syndrome&#xD;
&#xD;
          -  Estimated GFR &lt; 40 mL/min/1.73 m^2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ISIS 678354</keyword>
  <keyword>Fasting Triglycerides</keyword>
  <keyword>Apolipoprotein C-III</keyword>
  <keyword>Very Low-Density Lipoprotein Cholesterol</keyword>
  <keyword>High-Density Lipoprotein-Cholesterol</keyword>
  <keyword>Non-High-Density Lipoprotein-Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

